Achondroplasia
Drug research and approvals for achondroplasia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 9 studies of achondroplasia are recruiting on ClinicalTrials.gov, Health Canada has authorized 11 drug trials for it since 2013, FDA has 3 approved and 4 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 9
- Trials authorized in Canada: 11
- FDA orphan approvals: 3
- EU medicines: 1
Recruiting Now
Newest start dates first, of 9 recruiting on ClinicalTrials.gov ↗- Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With AchondroplasiaNCT07441876 · Phase 2 / Phase 3 · BioMarin Pharmaceutical · starts Apr 20, 2026
- Prospective Longitudinal Multicentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal DysplasiaNCT07388966 · Not reported · SYSNAV · starts Feb 6, 2026
- Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)NCT07169279 · Phase 2 · QED Therapeutics, a BridgeBio company · starts Nov 19, 2025
- A Study in Children With AchondroplasiaNCT07301463 · Not reported · Abbisko Therapeutics Co, Ltd · starts Jun 20, 2025
- A Study of TYRA-300 in Children With Achondroplasia: BEACH301NCT06842355 · Phase 2 · Tyra Biosciences, Inc · starts Mar 4, 2025
- A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of…NCT06079398 · Phase 2 · Ascendis Pharma A/S · starts Jan 23, 2024
- VIrtual STudy in Achondroplasia for the US (VISTA)NCT06168201 · Not reported · BioMarin Pharmaceutical · starts Feb 21, 2023
- Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)NCT05328050 · Not reported · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · starts Sep 1, 2021
- Achondroplasia Natural History Multicenter Clinical StudyNCT02597881 · Not reported · Johns Hopkins University · starts Apr 1, 2016
Trials Authorized in Canada
The 10 newest of 11; search them all in Canada trials| May 12, 2026 | A phase 3, randomized, double-blind, active controlled, multicenter trial investigating the efficacy and safety of dual therapy with once-weekly navepegritide…NAVEPEGRITIDE (TRANSCON CNP) / LONAPEGSOMATROPIN | Ascendis Pharma | Pending |
| Jan 22, 2026 | A multicenter, randomized, operationally seamless phase 2/3 study to evaluate the efficacy and safety of bmn 333 versus vosoritide in children with…BMN 333 / VOSORITIDE (BMN 111) | BioMarin Pharmaceutical | Ongoing |
| Nov 21, 2025 | A phase 2, multicenter, double-blind, randomized, placebo-controlled trial, evaluating safety, tolerability, and efficacy of subcutaneous doses of transcon cnp…NAVEPEGRITIDE (TRANSCON CNP) | Ascendis Pharma | Ongoing |
| Jul 28, 2025 | Phase 2b, randomized, double-blind, placebo-controlled clinical trial, preceded by a single ascending dose portion and a phase 2 open-label portion, to…INFIGRATINIB | QED THERAPEUTICS, INC. | Ongoing |
| May 28, 2025 | A phase 2b, multicenter, double-blind, randomized, placebo-controlled trial evaluating efficacy and safety of subcutaneous doses of navepegritide administered…NAVEPEGRITIDE (TRANSCON CNP) | Ascendis Pharma | Pending |
| Mar 19, 2025 | A multicenter, phase 2, dose-escalation/dose-expansion study of tyra-300 in children with achondroplasia with open growth plates: beach301DABOGRATINIB (TYRA-300) | TYRA BIOSCIENCES INC. | Ongoing |
| Nov 20, 2024 | Attach: a phase 2, multicenter, long-term, open label extension trial evaluating safety, tolerability, and efficacy of subcutaneous doses of transcon cnp…NAVEPEGRITIDE | Ascendis Pharma | Ongoing |
| Nov 27, 2023 | A phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of infigratinib in children 3 to <18 years of…INFIGRATINIB | QED THERAPEUTICS, INC. | Closed |
| Jan 3, 2023 | A phase 2b, multicenter, double-blind, randomized, placebo-controlled trial evaluating efficacy and safety of subcutaneous doses of transcon cnp administered…TRANSCON CNP | Ascendis Pharma | Closed |
| Oct 20, 2022 | Phase 2, open-label, long-term, extension (ole) study of infigratinib, an fgfr 1-3-selective tyrosine kinase inhibitor, in children with achondroplasia: propel…INFIGRATINIB (BGJ398, BBP-831) | QED THERAPEUTICS, INC. | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Feb 27, 2026 | Yuviwelto increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses | Ascendis Pharma Growth Disorders A/S | Approved |
| Oct 20, 2023 | Voxzogoto increase linear growth in pediatric patients with achondroplasia with open epiphyses | BioMarin Pharmaceutical, Inc. | Approved |
| Nov 19, 2021 | VoxzogoTo increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses | BioMarin Pharmaceutical, Inc. | Approved |
| Mar 16, 2026 | selective small molecular inhibitor of fibroblast growth…treatment of achondroplasia | Abbisko Therapeutics Co., Ltd. | Designated |
| Jul 25, 2023 | Small molecule fibroblast growth factor receptor 3…Treatment of Achondroplasia | Tyra Biosciences | Designated |
| Jan 25, 2022 | Anti-fibroblast growth factor receptor 3 antigen-binding…Treatment of Achondroplasia | Genzyme Corporation, a Sanofi Company | Designated |
| Aug 12, 2021 | InfigratinibTreatment of achondroplasia | QED Therapeutics, Inc. | Designated |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Aug 26, 2021 | Voxzogovosoritide · orphan | BioMarin International Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA